The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.
Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.
Effect demonstrated in multiple animal studies; human data sparse or extrapolated. Grades summarize evidence quality, not whether a compound is appropriate, legal, or risk-free.
Same compound, route-specific context. Switch forms instead of opening separate pages.
The route used in all three human pilot studies and in essentially all musculoskeletal animal research. Appropriate for tendon, ligament, muscle, and systemic anti-infla…
The route used in all three human pilot studies and in essentially all musculoskeletal animal research. Appropriate for tendon, ligament, muscle, and systemic anti-infla…
Open the full report at the dosing chapter for protocol rows, cycle context, and administration notes.
The standard form used in virtually all published animal research and in all three human pilot studies. Synthesized by solid-phase peptide synthesis as the acetate salt. This is the form to use for SubQ and IM injection protocols. Molecular weight and sequence are confirmed by mass spectrometry at 1,419.55 Da. Colorless solution after reconstitution.
The route used in all three human pilot studies and in essentially all musculoskeletal animal research. Appropriate for tendon, ligament, muscle, and systemic anti-inflammatory applications. Systemic distribution regardless of injection site — abdominal SubQ is standard. For specific musculoskeletal injuries, perilesional IM delivers higher local concentrations.
Direct injection near or into the injured structure. Higher local concentrations at the target tissue. Used in the Lee & Padgett knee pain pilot (intraarticular). More technically demanding and requires appropriate training. Not appropriate for DIY use in deep or complex anatomical targets.
BPC-157 is the compound the community has decided to use as if the animal evidence is sufficient proof of human efficacy — while the scientific establishment has largely declined to endorse it because the animal evidence, however consistent, comes overwhelmingly from one lab and has not been validated in human clinical trials. Both positions are defensible. What is not defensible is pretending the evidence is something it is not.
The central tension of this chapter resolves to a credibility problem, not a mechanism problem. The mechanisms — VEGFR2 angiogenesis, fibroblast recruitment, GI cytoprotection, mast cell stabilization — are plausible and partially independently confirmed. The 544-paper research base is real. The single-lab concentration is also real, and the 35:1 animal-to-human ratio in the systematic review is the clearest quantification of what that means in practice. The compound the community treats as the most proven healing peptide is the compound with the most concentrated research provenance problem in the entire field.
The favorable safety signal from the three published human pilots is meaningful. No adverse events across approximately 30 participants using IV, intravesicular, and intraarticular routes is a genuine positive data point. It does not establish long-term safety, does not confirm therapeutic efficacy via controlled trial, and does not resolve the cancer safety question raised by the pro-angiogenic mechanism — but it does suggest the compound is not immediately dangerous at the doses studied.
The default page keeps the decision layer visible first: summary, routes, evidence, and risks. Open the full report for mechanisms, chapter sections, citations, updates, and print/share controls.
The Body's Own Repair Signal — And the Evidence Gap Between What It Does and How People Use It
Scope appropriateness is the question: local gut peptides are being stacked for barrier integrity and inflammatory signaling, not for systemic regeneration claims.
Adds KPV’s local gut anti-inflammatory signal to the GLOW recovery-and-skin stack.